⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235500 | 1.00 | — | — | |
| SCHEMBL7936305 | 0.97 | PNMT (0.32) | — | |
| Hydrochloric Acid SCHEMBL21957165 | 0.97 | — | — | |
| SCHEMBL894123 | 0.85 | — | — | |
| SCHEMBL325293 | 0.85 | — | — | |
| SCHEMBL232815 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL17202018 | 0.83 | KDM4E (0.42) | — | |
| Hydrochloric Acid SCHEMBL21817810 | 0.83 | KDM4E (0.42) | — | |
| SCHEMBL1036841 | 0.83 | CYP2D6 (0.34) | — | |
| SCHEMBL12100332 | 0.83 | CYP2D6 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069571-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2026-03-12 | — | — | US | disclosed |
| EP-4426688-B1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA LTD (GB) | 2025-12-03 | — | — | EP | disclosed |
| EP-4642773-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-11-05 | — | — | EP | disclosed |
| US-20240376056-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. | 2024-11-14 | — | — | US | disclosed |
| WO-2024141444-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-04 | — | — | WO | disclosed |
| EP-4366829-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | Dice Alpha, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117957212-A | IL-17A modulators based on phenylacetamide and uses thereof | 戴斯阿尔法公司 | 2024-04-30 | — | — | CN | disclosed |
| US-11952367-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-04-09 | — | — | US | disclosed |
| US-20240067633-A1 | KETOHEXOKINASE INHIBITOR AND USE THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| WO-2024008909-A1 | INHIBITORS OF CORONAVIRUS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20220227736-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022129913-A1 | ALKYNE DERIVATIVES AS INHIBITORS OF C-ABL | BENEVOLENTAI BIO LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| US-20210363152-A1 | AMINOAZINE AMIDES | HOFFMANN LA ROCHE (US) | 2021-11-25 | — | — | US | disclosed |
| WO-2021038419-A1 | KINASE INHIBITORS AND METHODS OF SYNTHESIS AND TREATMENT | INSILICO MEDICINE IP LIMITED (CN) | 2021-03-04 | — | — | WO | disclosed |
| WO-2020119896-A1 | HETEROCYCLIC INHIBITORS OF ATX | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-18 | — | — | WO | disclosed |
| US-9994547-B2 | Heteroarylamide inhibitors of TBK1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170313675-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TAKEDA CALIFORNIA, INC. | 2017-11-02 | — | — | US | disclosed |
| WO-2016057338-A1 | HETEROARYLAMIDE INHIBITORS OF TBK1 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-14 | — | — | WO | disclosed |